Teva's UZEDY Outperforms Rivals in Schizophrenia Treatment, Cuts Costs
Event summary
- Teva presented real-world data at Psych Congress (Sept 15-19, 2026) showing UZEDY reduced emergency care and healthcare costs by over $1,000 per patient per month compared to competitors.
- UZEDY demonstrated 3.6x higher adherence and 80% lower discontinuation rates versus risperidone microspheres in schizophrenia patients.
- Bipolar I disorder patients switching to UZEDY from oral antipsychotics experienced 47% treatment failure vs. 63% for those switching to other oral options.
- UZEDY is the only long-acting, subcutaneous formulation of risperidone available in both one- and two-month dosing intervals.
The big picture
Teva's data positions UZEDY as a potential game-changer in schizophrenia treatment, addressing critical issues of patient adherence and healthcare system costs. This comes as the mental health sector increasingly focuses on long-acting therapies to improve outcomes and reduce the burden of chronic conditions. The findings could accelerate adoption of subcutaneous formulations in psychiatric care, particularly if payers respond to the demonstrated cost savings.
What we're watching
- Market Differentiation
- Whether UZEDY's superior adherence and cost metrics can drive market share gains against established long-acting injectables.
- Regulatory Dynamics
- How FDA and other regulators may respond to this real-world evidence in future approval or labeling decisions.
- Commercial Execution
- The pace at which Teva can convert these clinical advantages into sustained revenue growth.
Related topics